Analysis of DNA methylation in cancer: location revisited.

Koch A1, Joosten SC2, Feng Z1, de Ruijter TC2, Draht MX1, Melotte V1, Smits KM1,2, Veeck J2, Herman JG3, Neste LV1, Criekinge WV4, De Meyer T5, Engeland MV6.

Author information

Erratum in

Author Correction: Analysis of DNA methylation in cancer: location revisited. [Nat Rev Clin Oncol. 2018]

Abstract

Changes in DNA methylation in cancer have been heralded as promising targets for the development of powerful diagnostic, prognostic, and predictive biomarkers. Despite the existence of more than 14,000 scientific publications describing DNA methylation-based biomarkers and their clinical associations in cancer, only 14 of these biomarkers have been translated into a commercially available clinical test. Methodological and experimental obstacles are both major causes of this disparity, but the genomic location of a DNA methylation-based biomarker is an intrinsic and essential property that also has an important and often overlooked role. Here, we examine the importance of the location of DNA methylation for the development of cancer biomarkers, and take a detailed look at the genomic location and other relevant characteristics of the various biomarkers with commercially available tests. We also emphasize the value of publicly available databases for the development of DNA methylation-based biomarkers and the importance of accurate reporting of the full methodological details of research findings.